IGF-1 LR3vsTesamorelin

IGF-1 LR3 is an 83-amino-acid analogue of native IGF-1 (70 amino acids) featuring two critical modifications: an arginine substitution at position 3 (replacing glutamic acid) and a 13-amino-acid N-terminal extension peptide. These modifications dramatically reduce binding affinity for the six IGF binding proteins (IGFBP-1 through IGFBP-6) that normally sequester over 98% of circulating IGF-1, effectively increasing the free, bioactive fraction by orders of magnitude.

Free IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase structurally similar to the insulin receptor. Receptor activation triggers autophosphorylation and recruitment of insulin receptor substrate (IRS) proteins, activating two major downstream cascades: the PI3K/Akt/mTOR pathway (driving protein synthesis, cell survival, and glucose uptake) and the Ras/MAPK/ERK pathway (promoting cell proliferation and differentiation). The potent activation of mTORC1 through Akt directly stimulates ribosomal protein S6 kinase and inhibits 4E-BP1, dramatically increasing the rate of translation and muscle protein synthesis.

What makes IGF-1 LR3 particularly potent for muscle growth compared to GH or native IGF-1 is its ability to promote muscle cell hyperplasia — the creation of entirely new muscle cells from satellite cell differentiation — rather than solely hypertrophy (enlarging existing cells). IGF-1R signaling in satellite cells activates MyoD and myogenin expression, driving proliferation and fusion into existing myofibers. The 20-30 hour half-life of LR3 (compared to 12-15 minutes for native IGF-1) means sustained receptor activation, continuous anabolic signaling, and significantly greater biological potency per dose. However, this same potency carries risks: strong insulin-like hypoglycemic effects, potential promotion of tumor growth through anti-apoptotic signaling, and possible organ hypertrophy with chronic use.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.